Y MAbs Ownership
| YMAB Stock | USD 11.92 0.04 0.34% |
Shares in Circulation | First Issued 2017-09-30 | Previous Quarter 44 M | Current Value 44.6 M | Avarage Shares Outstanding 40 M | Quarterly Volatility 5.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
YMAB |
YMAB Stock Ownership Analysis
About 12.0% of the company outstanding shares are owned by insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.04. Y mAbs Therapeutics recorded a loss per share of 0.54. The entity had not issued any dividends in recent years. Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Y-Mabs Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people. For more information please call Michael Rossi at 646 885 8505 or visit https://www.ymabs.com.Besides selling stocks to institutional investors, Y MAbs also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Y MAbs' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Y MAbs' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Y MAbs Quarterly Liabilities And Stockholders Equity |
|
Y MAbs Insider Trades History
About 12.0% of Y mAbs Therapeutics are currently held by insiders. Unlike Y MAbs' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Y MAbs' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Y MAbs' insider trades
YMAB Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Y MAbs is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Y mAbs Therapeutics backward and forwards among themselves. Y MAbs' institutional investor refers to the entity that pools money to purchase Y MAbs' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Caligan Partners Lp | 2024-06-30 | 582.1 K | Boothbay Fund Management, Llc | 2024-09-30 | 557.4 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 477.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 406.3 K | Millennium Management Llc | 2024-06-30 | 349.8 K | Northern Trust Corp | 2024-09-30 | 337.3 K | Charles Schwab Investment Management Inc | 2024-09-30 | 279.6 K | Citadel Advisors Llc | 2024-09-30 | 274.5 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 176.1 K | Paradigm Biocapital Advisors Lp | 2024-09-30 | 4.1 M | Blackrock Inc | 2024-06-30 | 2.9 M |
Y mAbs Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Y MAbs insiders, such as employees or executives, is commonly permitted as long as it does not rely on Y MAbs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Y MAbs insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Y MAbs Outstanding Bonds
Y MAbs issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Y mAbs Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most YMAB bonds can be classified according to their maturity, which is the date when Y mAbs Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| XEROX HLDGS P Corp BondUS98421MAB28 | View | |
| XEROX HLDGS P Corp BondUS98421MAA45 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US98420EAB11 Corp BondUS98420EAB11 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Y MAbs Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 20th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 8th of July 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.921 | Quarterly Revenue Growth (0.1) | Return On Assets (0.12) | Return On Equity (0.25) |
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.